Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UNICEF Strikes Deal To Buy Russia’s Sputnik V Vaccine

Supply Will Depend On Emergency Use Listing By The WHO

Executive Summary

A new procurement deal will add to the rollout of COVID-19 vaccines at global level. However, the leaders of the COVAX Facility say that by the end of June they will face a shortfall of 190 million doses, mainly because of the crisis in India, and are calling on wealthier countries to increase their donations.

You may also be interested in...



Coronavirus Notebook: COVAX Exceeds Vaccine Funding Target, Canada OKs Mix-And-Match Dosing

In a sign of growing support for more equitable vaccine distribution, many donors have pledged either money or doses to lower-income economies. The World Health Organization has granted emergency use listing to another Chinese vaccine, and Russia’s Sputnik V is to be produced in Bahrain for the MENA region.

EU ‘Among World Leaders’ In COVID-19 Vaccination

Vaccination campaigns against the coronavirus in the EU are recovering ground lost in the early days of the pandemic, although the European Commission says “we need to keep up the effort.”

Coronavirus Notebook: EU Industry Claims ‘Undeniable’ Role Of IP, UK Targets Younger At-Risk Groups For Vaccination

Draft EU legislation on tackling cross-border health threats has taken another step forward, as health authorities say the Delta variant of the SARS-CoV-2 virus will be the “globally dominant strain” over the coming months.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel